25 LLC’s Vanda Pharmaceuticals VNDA Stock Holding History

25 LLC’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-82	Closed	-$495	–	553
2023 Q2	$495	Buy	82 +2	+3%	+$13	﹤0.01%	550
2023 Q1	$555	Buy	+80	New	+$562	﹤0.01%	289

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

25 LLC's VNDA Position: Q3 2023 in Review

25 LLC sold out of Vanda Pharmaceuticals (VNDA) in Q3 2023, closing a stake of 82 shares — an estimated $495 sold.

25 LLC first reported a position in VNDA in Q1 2023 and held it in 2 quarters. The position peaked at $555 in Q1 2023. 179 funds tracked by Wall St. Rank hold VNDA as of Q3 2023.

25 LLC reported no remaining Vanda Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
25 LLC sold 82 Vanda Pharmaceuticals shares in Q3 2023, an estimated $495.
25 LLC first reported a position in Vanda Pharmaceuticals in Q1 2023 and held it in 2 quarters.
25 LLC's Vanda Pharmaceuticals position peaked at $555 in Q1 2023.
179 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2023.

Based on 25 LLC's 13F filing for Q3 2023, filed 18 Oct 2023.